Generic Trintellix ( Vortioxetine )

Buy Generic Trintellix (Vortioxetine) without prescription in Canada

In our Canadian pharmacy, you can buy Trintellix (Vortioxetine) without a prescription, with delivery across Canada within 5‑14 days. Discreet and anonymous packaging.

Trintellix (vortioxetine hydrobromide) is a multimodal antidepressant used for the treatment of major depressive disorder (MDD) in adults. It works through a combination of serotonin reuptake inhibition and direct modulation of multiple serotonin receptors, including acting as an antagonist at 5‑HT₃, 5‑HT₇, and 5‑HT_1D receptors, a partial agonist at 5‑HT_1B receptors, and an agonist at 5‑HT_1A receptors. This unique profile is thought to contribute to its efficacy in improving mood and cognitive symptoms associated with depression, such as difficulties with concentration and decision‑making.

Usual adult dose: The recommended starting dose is 10 mg taken orally once daily, with or without food. Depending on individual patient response and tolerability, the dose may be increased to a maximum of 20 mg once daily or decreased to a minimum of 5 mg once daily. For patients who do not tolerate higher doses, 5 mg per day may be an effective maintenance dose. The lowest effective dose of 5 mg per day should be used as the starting dose in elderly patients (≥ 65 years of age). The maximum recommended dose is 20 mg per day.

Dosage form: Film‑coated tablets available in 5 mg, 10 mg, and 20 mg strengths.

Onset of action: Some improvement in depressive symptoms may be observed within the first 2 weeks of treatment, although the full antidepressant effect typically requires 6 to 8 weeks of continuous therapy. Cognitive improvements may also be seen over this time frame.

Duration of action: The elimination half‑life of vortioxetine is approximately 66 hours, supporting once‑daily dosing. Steady‑state plasma concentrations are achieved within approximately 2 weeks of regular administration.

Alcohol recommendation: Alcohol consumption should be avoided during treatment with Trintellix. Alcohol can worsen depression and anxiety symptoms and may increase the risk of side effects such as dizziness and drowsiness.

Most common side effects: Nausea (21–32%), constipation, vomiting, and dizziness. Nausea is the most frequently reported adverse effect and is typically mild to moderate, peaking during the first week of therapy and diminishing over time. Sexual dysfunction and significant weight gain are reported less frequently than with many other antidepressants.

Would you like to try Trintellix (Vortioxetine) without a prescription?

General Information about Trintellix (Vortioxetine)

• INN (International Nonproprietary Name): Vortioxetine (as vortioxetine hydrobromide).
• Brand names available in Canada: Trintellix® (Lundbeck Canada Inc.). Generic versions include APO‑Vortioxetine (Apotex Inc.), and other manufacturer‑branded generics.
• ATC code: N06AX26.
• Dosage forms and strengths: Film‑coated tablets: 5 mg, 10 mg, and 20 mg.
• Manufacturers in Canada: Lundbeck Canada Inc., Apotex Inc., and other generic pharmaceutical companies.
• Registration status in Canada: Approved by Health Canada (Notice of Compliance issued October 22, 2014). DINs: 02432919 (5 mg), 02432927 (10 mg), 02432935 (15 mg), 02432943 (20 mg).
• OTC / Rx classification: Prescription only (Rx). Schedule I drug under the Controlled Drugs and Substances Act.

Mechanism of Action and Pharmacology

Vortioxetine is a novel antidepressant with a multimodal mechanism of action that combines serotonin (5‑HT) reuptake inhibition with direct modulation of multiple serotonin receptor subtypes. Specifically, vortioxetine is an inhibitor of the serotonin transporter (SERT), which increases the synaptic availability of serotonin. In addition, it acts as an antagonist at 5‑HT₃, 5‑HT₇, and 5‑HT_1D receptors, a partial agonist at 5‑HT_1B receptors, and an agonist at 5‑HT_1A receptors. This receptor activity profile is thought to differentiate vortioxetine from selective serotonin reuptake inhibitors (SSRIs) and serotonin‑norepinephrine reuptake inhibitors (SNRIs), contributing to its effects on multiple neurotransmitter systems, including serotonergic, noradrenergic, dopaminergic, cholinergic, histaminergic, and glutamatergic pathways. Preclinical studies have demonstrated that vortioxetine enhances neurotransmission in brain structures associated with major depressive disorder, and it has shown procognitive effects in animal models of memory, cognition, and executive function.

After oral administration, vortioxetine is slowly but well absorbed, with peak plasma concentrations reached within 7 to 11 hours. The absolute bioavailability is approximately 75%. Food does not significantly affect absorption. The drug is extensively metabolized in the liver, primarily by cytochrome P450 2D6, and to a lesser extent by CYP3A4/3A5, CYP2C9, CYP2A6, CYP2C8, and CYP2B6. The elimination half‑life is approximately 66 hours, and steady‑state plasma concentrations are achieved within approximately 2 weeks of once‑daily dosing. Plasma protein binding is high (approximately 98–99%). Approximately 59% of a dose is excreted in the urine and 26% in the faeces, predominantly as metabolites.

Indications

• Major Depressive Disorder (MDD): Trintellix is indicated for the treatment of major depressive disorder in adults. Efficacy in providing symptomatic relief of MDD has been demonstrated in short‑term trials of up to 8 weeks’ duration; efficacy in maintaining an antidepressant response has been demonstrated for up to 24 weeks.
• Physicians who elect to use Trintellix for extended periods should periodically re‑evaluate the usefulness of the drug for individual patients.
• Trintellix is not indicated for use in paediatric patients. Safety and efficacy in children and adolescents under 18 years of age have not been established.

Important Warnings and Precautions

At‑risk groups

• Pregnancy: There are no adequate and well‑controlled studies of vortioxetine in pregnant women. Trintellix should be used during pregnancy only if the potential benefit clearly outweighs the potential risk to the foetus. Infants exposed to serotonergic antidepressants late in the third trimester may develop postnatal complications requiring prolonged hospitalization, respiratory support, and tube feeding. There is a potential for increased risk of postpartum hemorrhage with drugs that affect serotonin reuptake.
• Breastfeeding: Vortioxetine is excreted in human breast milk. Trintellix is not recommended during breastfeeding. A decision must be made whether to discontinue breastfeeding or to discontinue the drug, taking into account the importance of the medication to the mother.
• Paediatrics (< 18 years): Safety and efficacy have not been established in children and adolescents. Trintellix is not indicated for use in this population. Antidepressants increase the risk of suicidal thinking and behaviour in children, adolescents, and young adults in short‑term studies.
• Elderly (≥ 65 years): The lowest effective dose of 5 mg/day should always be used as the starting dose. No dose adjustment is required based on age alone, but caution is advised because elderly patients may be more sensitive to the adverse effects of the drug, including hyponatraemia and the risk of falls.
• Hepatic impairment: Caution is advised in patients with moderate or severe hepatic impairment. Vortioxetine exposure is increased in patients with hepatic impairment; the drug should be used at lower doses in these patients.
• Renal impairment: Caution is advised in patients with severe renal insufficiency. Vortioxetine has not been studied in patients with severe renal impairment, and exposure may be increased.
• Bipolar disorder: Screen for bipolar disorder, mania, and hypomania prior to starting treatment. Trintellix may precipitate a manic or hypomanic episode in patients with undiagnosed bipolar disorder. Discontinue use in any patient entering a manic phase.
• Seizure disorders: Use with caution in patients who have a history of seizures or in patients with unstable epilepsy. The drug has not been systematically evaluated in patients with seizure disorders.
• Angle‑closure glaucoma: Vortioxetine can cause pupillary dilation, which may trigger an acute attack of angle‑closure glaucoma in susceptible individuals. Patients at risk should have an ophthalmologic evaluation before starting therapy.
• Hyponatraemia: Cases of hyponatraemia have been reported with serotonergic antidepressants, including Trintellix. Caution is advised in elderly patients, those taking diuretics, and those who are otherwise volume‑depleted.
• Abnormal bleeding: Vortioxetine, like other serotonergic antidepressants, may cause abnormal bleeding, including gastrointestinal and cutaneous bleeding. Caution is advised in patients taking anticoagulants or antiplatelet agents.
• Bone fracture risk: Epidemiological studies have shown an association between the use of serotonergic antidepressants and an increased risk of bone fractures. The mechanism is not fully understood.
• Sexual dysfunction: Cases of long‑lasting sexual dysfunction where symptoms have continued despite discontinuation of SSRIs/SNRIs have been reported.
• Allergy: Do not take Trintellix if you have a known hypersensitivity to vortioxetine hydrobromide or any excipient in the formulation.

Driving and alcohol

Trintellix may cause dizziness, somnolence, and other central nervous system effects that could impair the ability to drive and operate machinery. Patients should be cautioned about driving or operating hazardous machinery until they are reasonably certain that Trintellix does not adversely affect their mental alertness and motor coordination. Alcohol consumption should be avoided during treatment with Trintellix. Alcohol can worsen depression, increase the risk of side effects such as dizziness and sedation, and may interfere with the effectiveness of the medication.

Dosage Instructions

• Standard adult dose: The recommended starting dose is 10 mg administered orally once daily, without regard to meals. Depending on individual patient response and tolerability, the dose may be increased to a maximum of 20 mg once daily or decreased to a minimum of 5 mg once daily.
• Patients who do not tolerate higher doses: Patients who do not tolerate the 10 mg or 20 mg dose may be maintained on 5 mg orally once daily.
• Elderly patients (≥ 65 years): The lowest effective dose of 5 mg/day should be used as the starting dose. The dose may be titrated upward based on individual response and tolerability.
• Patients taking strong CYP2D6 inhibitors: The dose of Trintellix should be reduced by half when co‑administered with strong CYP2D6 inhibitors (e.g., bupropion, fluoxetine, paroxetine, quinidine).
• Patients taking strong CYP inducers: An increase in the Trintellix dose should be considered when a strong CYP inducer (e.g., rifampin, carbamazepine, phenytoin) is co‑administered for more than 14 days. The maximum dose should not exceed three times the original dose.
• CYP2D6 poor metabolizers: The maximum recommended dose is 10 mg/day.
• Switching to or from an MAOI: At least 14 days must elapse between discontinuing an MAOI intended to treat psychiatric disorders and starting Trintellix. At least 21 days must elapse between stopping Trintellix and starting an MAOI intended to treat psychiatric disorders.
• Administration: Trintellix may be taken with or without food. The tablets should be swallowed whole with a glass of water.
• Missed dose: If a dose is missed, it should be taken as soon as remembered. If it is close to the time of the next dose, the missed dose should be skipped and the regular schedule resumed. Do not double the dose.
• Discontinuation: Trintellix may be abruptly discontinued; however, headache and muscle tension occurred at doses of 15 mg to 20 mg/day. To avoid potential adverse reactions, decreasing the dose to 10 mg/day for one week before complete discontinuation is recommended.

Side Effects and Contraindications

• Very common side effects (≥ 10%): Nausea (21–32%), which is typically mild to moderate in severity and peaks during the first week of therapy.
• Common side effects (1‑10%): Constipation, vomiting, diarrhoea, dry mouth, dizziness, somnolence, pruritus (generalized), and abnormal dreams.
• Less common but serious side effects: Serotonin syndrome (a potentially life‑threatening condition characterized by mental status changes, autonomic instability, neuromuscular abnormalities, and gastrointestinal symptoms), neuroleptic malignant syndrome‑like symptoms, hyponatraemia, abnormal bleeding (including gastrointestinal and cutaneous bleeding), activation of mania or hypomania, seizures, and angle‑closure glaucoma.
• Post‑marketing reports: Hypersensitivity reactions (including anaphylaxis, angioedema, and urticaria), pancreatitis, and bone fractures.
• Discontinuation symptoms: Abrupt discontinuation may lead to headache and muscle tension, particularly at doses of 15 mg to 20 mg/day. A gradual dose taper is recommended.
• Contraindications: Hypersensitivity to vortioxetine hydrobromide or any excipient in the formulation. Concomitant use with monoamine oxidase inhibitors (MAOIs) intended to treat psychiatric disorders, including linezolid and intravenous methylene blue. Starting Trintellix in a patient who is being treated with an MAOI, or within 14 days of discontinuing an MAOI intended to treat psychiatric disorders. Starting an MAOI intended to treat psychiatric disorders in a patient who is being treated with Trintellix, or within 21 days of discontinuing Trintellix.

Drug Interactions

• Monoamine oxidase inhibitors (MAOIs) — contraindicated: Concomitant use of Trintellix with MAOIs, including linezolid and intravenous methylene blue, increases the risk of serotonin syndrome and is contraindicated. A 14‑day washout from MAOIs is required before starting Trintellix, and a 21‑day washout from Trintellix is required before starting an MAOI.
• Other serotonergic drugs: Concomitant use of Trintellix with other serotonergic agents increases the risk of serotonin syndrome. These include other SSRIs, SNRIs, tricyclic antidepressants, triptans, opioids (e.g., fentanyl, tramadol), lithium, buspirone, amphetamines, tryptophan, and St. John’s wort. Monitor for symptoms of serotonin syndrome if co‑administration is clinically necessary.
• Strong CYP2D6 inhibitors: Drugs such as bupropion, fluoxetine, paroxetine, and quinidine can significantly increase vortioxetine plasma concentrations. The dose of Trintellix should be reduced by half when co‑administered with strong CYP2D6 inhibitors.
• Strong CYP inducers: Drugs such as rifampin, carbamazepine, and phenytoin can decrease vortioxetine plasma concentrations, potentially reducing therapeutic efficacy. An increase in the Trintellix dose should be considered; the maximum dose should not exceed three times the original dose.
• Drugs that interfere with hemostasis: Trintellix, like other serotonergic antidepressants, may increase the risk of bleeding when co‑administered with antiplatelet agents (e.g., aspirin, clopidogrel) and anticoagulants (e.g., warfarin, heparin). For patients taking warfarin, carefully monitor the international normalized ratio (INR).
• Drugs highly bound to plasma protein: Trintellix is highly protein‑bound (98–99%). Concomitant use with other highly protein‑bound drugs may increase free concentrations of either drug. Monitor for adverse reactions.
• Alcohol and food: Alcohol should be avoided, as it may worsen depression and increase the risk of side effects. Food does not affect the absorption of vortioxetine.

Practical Advice

• Administration: Take Trintellix exactly as prescribed by your doctor, once daily, with or without food. Swallow the tablet whole with a glass of water. Try to take it at the same time each day to maintain consistent blood levels.
• Monitoring: Regular follow‑up with your doctor is essential, particularly during the first weeks of treatment and after dosage changes. Monitor for clinical worsening, emergence of suicidal thoughts or behaviour, and unusual changes in mood or behaviour. Blood pressure and heart rate should be monitored periodically. In patients at risk, serum sodium should be checked, particularly in the elderly and those taking diuretics.
• Storage: Store at room temperature (15‑30 °C) in a dry place, protected from moisture and light. Keep out of the reach and sight of children.
• Lifestyle: Trintellix is most effective when used as part of a comprehensive treatment plan that includes psychotherapy, lifestyle changes, and social support. Maintain a balanced diet and regular sleep schedule. Avoid alcohol and recreational drugs. Do not drive or operate heavy machinery until you know how the medication affects you. Rising slowly from a sitting or lying position may help minimize dizziness.
• Missed dose: If you miss a dose, take it as soon as remembered. If it is close to the time of your next dose, skip the missed dose and resume your regular schedule. Do not double the dose.
• When to seek medical review: Contact your doctor immediately if you experience signs of serotonin syndrome (agitation, confusion, rapid heart rate, high fever, muscle rigidity, seizures), manic episode (extreme elation, racing thoughts, risk‑taking behaviour), abnormal bleeding, severe allergic reaction (rash, swelling of the face, tongue, or throat, difficulty breathing), or worsening depression with suicidal thoughts.
• Disposal: Return unused or expired medication to a pharmacy for safe disposal. Do not flush down the toilet or discard in household waste.

Alternative Medications

• Selective serotonin reuptake inhibitors (SSRIs): Sertraline (Zoloft), escitalopram (Cipralex), fluoxetine (Prozac), paroxetine (Paxil), and citalopram (Celexa) are first‑line antidepressants for major depressive disorder. They are generally well tolerated, but they may be more likely to cause sexual dysfunction and gastrointestinal side effects than vortioxetine.
• Serotonin‑norepinephrine reuptake inhibitors (SNRIs): Venlafaxine (Effexor), duloxetine (Cymbalta), and desvenlafaxine (Pristiq) are first‑line antidepressants that target both serotonin and norepinephrine. They may be particularly useful when pain or fatigue is a prominent symptom.
• Atypical antidepressants: Mirtazapine (Remeron) is effective for depression with insomnia or poor appetite; bupropion (Wellbutrin) is an activating antidepressant with a low incidence of sexual dysfunction and weight gain; agomelatine (Valdoxan) improves sleep without daytime sedation. Each has a unique receptor profile that may suit different patient needs.
• Tricyclic antidepressants (TCAs): Amitriptyline (Elavil) and nortriptyline (Aventyl) are older agents that are effective but have a higher burden of anticholinergic side effects and cardiotoxicity in overdose. They are generally reserved for treatment‑resistant cases.
• Vilazodone (Viibryd): Another multimodal antidepressant that combines SSRI activity with 5‑HT_1A receptor partial agonism. It is not currently marketed in Canada.
• Levomilnacipran (Fetzima): An SNRI with greater potency for norepinephrine reuptake inhibition. It is approved for MDD in the United States but is not currently marketed in Canada.
• Non‑pharmacological approaches: Cognitive behavioural therapy (CBT), interpersonal therapy (IPT), and behavioural activation are evidence‑based psychotherapies for depression. Exercise, mindfulness‑based stress reduction, and good sleep hygiene are important complementary measures.

Clinical Efficacy

The efficacy of vortioxetine for the treatment of major depressive disorder has been established in multiple randomized, double‑blind, placebo‑controlled clinical trials. A systematic review and meta‑analysis of 14 short‑term (6‑ to 8‑week) trials demonstrated that vortioxetine was significantly superior to placebo in reducing depressive symptom severity, as measured by the Montgomery‑Åsberg Depression Rating Scale (MADRS) and the Hamilton Depression Rating Scale (HAM‑D24). The response rate for vortioxetine (defined as a ≥ 50% reduction in MADRS total score) was approximately 46–62% compared with 30–35% for placebo. The number needed to treat (NNT) for response was approximately 6–7.

In a head‑to‑head comparison, the VIVRE study demonstrated that vortioxetine was significantly better than desvenlafaxine in improving overall functioning, as well as daily, social, and cognitive functioning, in patients with MDD who had shown an inadequate response to prior SSRI therapy. The COMPLETE study found that after 8 weeks of vortioxetine treatment, 70.4% of patients no longer reported emotional blunting, and 53.7% achieved remission from their depressive symptoms (defined as a MADRS total score ≤ 10).

A maintenance study in adults demonstrated that vortioxetine significantly increased the time to relapse compared with placebo over a period of up to 24 weeks, supporting its efficacy for long‑term maintenance therapy. In elderly patients (aged 65 years and older), a dedicated randomized controlled trial demonstrated that vortioxetine was effective and well tolerated.

The CADTH Canadian Drug Expert Committee (CDEC) has recommended that vortioxetine be reimbursed for the treatment of major depressive disorder in adults, with the condition that it be prescribed as an alternative for patients who have failed, are intolerant to, or have a contraindication to at least two other antidepressants. The clinical guidelines from the Canadian Network for Mood and Anxiety Treatments (CANMAT) list vortioxetine as a first‑line antidepressant for the treatment of MDD, noting its potential advantages for cognitive symptoms and its favourable tolerability profile, particularly with regard to sexual dysfunction and weight gain.

Important:

Trintellix (vortioxetine) is a prescription medication that should be used only under the supervision of a qualified healthcare professional. It may increase the risk of suicidal thoughts and behaviour, particularly in children, adolescents, and young adults under 24 years of age. All patients, regardless of age, should be closely monitored for clinical worsening, suicidality, or unusual changes in behaviour, especially during the first few months of treatment and after dosage changes. This medication is not approved for use in paediatric patients. A rare but potentially life‑threatening serotonin syndrome may occur, particularly when Trintellix is combined with other serotonergic drugs. If you experience symptoms such as agitation, confusion, rapid heart rate, high fever, muscle rigidity, or seizures, seek immediate medical attention. Do not discontinue the medication abruptly without consulting your doctor, as this may cause withdrawal symptoms. Avoid alcohol during treatment. Trintellix is contraindicated with MAOIs; a 14‑day washout period is required before starting Trintellix after stopping an MAOI, and a 21‑day washout period is required before starting an MAOI after stopping Trintellix. This information is not a substitute for professional medical advice, diagnosis, or treatment.

Get Generic Trintellix - Shipping across Canada